Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
about
Hepatic manifestations of non-steroidal inflammatory bowel disease therapyConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsLow-dose naltrexone therapy improves active Crohn's diseaseMonocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumabInflammatory bowel disease and demyelination: more than just a coincidence?Vedolizumab for the treatment of moderately to severely active ulcerative colitis.Recent trends and future directions for the medical treatment of ulcerative colitis.
P2860
Q26773684-FCB8F573-13FD-4200-8990-FD2D17686180Q26830569-68510398-7E20-4385-8B03-F9FE81D6BF25Q28283321-875076A6-58FA-4695-8BD5-A2C0DF8F7C6CQ34906120-4591615A-E716-4C34-833C-1A3B38D1AFB7Q38184633-06AE2408-F23D-47EF-A183-C400708B14C1Q38425873-7D5EA1C4-2430-4856-9586-798BACEC75CDQ38815035-9A69530A-2C4A-42DB-9205-40DE80DE6456
P2860
Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
@ast
Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
@en
type
label
Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
@ast
Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
@en
prefLabel
Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
@ast
Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
@en
P2093
P2860
P356
P1476
Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
@en
P2093
Douglas R Allington
Kendra A Keeley
Michael P Rivey
P2860
P304
P356
10.1345/APH.1G134
P407
P577
2005-10-11T00:00:00Z